Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Deucrictibant by Pharvaris for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency): Likelihood of Approval
Deucrictibant is under clinical development by Pharvaris and currently in Phase III for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH]...